Related Experiment Video

Updated: Oct 17, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2)

K Sugiyama1, M Shimizu, T Akiyama

  • 1Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan.

International Journal of Cancer
|March 4, 2000
PubMed

Insights

UCN-01 enhances the anti-cancer drug mitomycin C (MMC) effectiveness, particularly in cancer cells with defective p53. This protein kinase inhibitor may offer new chemotherapy options for patients with p53-mutated tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • UCN-01 (7-hydroxystaurosporine) is a protein kinase inhibitor investigated for anti-cancer properties.
  • Previous research indicated UCN-01 enhances anti-tumor activity of mitomycin C (MMC).
  • UCN-01 selectively augments cytotoxicity of DNA-damaging agents in p53-defective cells by abrogating cell cycle arrest.

Purpose of the Study:

  • To investigate the selective enhancement of mitomycin C (MMC) cytotoxicity by UCN-01 in human p53 mutant cell lines.
  • To compare the effect of UCN-01 on MMC cytotoxicity in p53 mutant versus p53 wild-type cell lines.
  • To elucidate the role of cell cycle arrest and p53 status in mediating the synergistic effects of UCN-01 and MMC.

Main Methods:

  • Utilized human p53 mutant and wild-type cancer cell lines.
  • Administered UCN-01 in combination with mitomycin C (MMC).
  • Assessed cytotoxicity using TUNEL assay for DNA breaks and apoptosis.
  • Performed detailed cell-cycle analysis to evaluate S and G2 phase arrest.
  • Monitored p21/WAF1 induction in response to MMC treatment.

Main Results:

  • UCN-01 significantly enhanced MMC cytotoxicity in human p53 mutant cell lines, with minimal effect in p53 wild-type lines.
  • The combination of MMC and UCN-01 increased DNA breaks and apoptosis in p53-defective A431 cells.
  • UCN-01 abrogated MMC-induced S and G2 phase arrest in p53-defective cells, and to a lesser extent in p53 wild-type cells.
  • In p53 wild-type cells, p21/WAF1 induction by MMC was delayed, and UCN-01's abrogation of arrest occurred before significant p53 response.

Conclusions:

  • UCN-01 selectively potentiates mitomycin C (MMC) cytotoxicity in p53-defective cancer cells.
  • The abrogation of cell cycle arrest by UCN-01 contributes to enhanced MMC efficacy in p53-mutant cancers.
  • UCN-01 represents a potential new therapeutic strategy to improve MMC-based chemotherapy outcomes, especially for patients with p53-defective tumors.

More Related Videos

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...